Tesamorelin vs Growth-hormone-releasing hormone
An FDA-approved GHRH analog that selectively trims visceral fat. The hypothalamic signal that tells the pituitary to release GH. Side by side: type, evidence tier, receptor, molecular weight, and half-life — the same fields as each monograph, rearranged so the engineering difference is visible.
Tesamorelin | Growth-hormone-releasing hormone GHRH | |
|---|---|---|
| Also known as | Egrifta | — |
| Type | Analog | Endogenous |
| Evidence | Clinical | Established |
| Family | Growth & repair | Growth & repair |
| Class | Stabilized GHRH(1-44) analog | Hypothalamic releasing peptide (44 aa) |
| Receptor | GHRH receptor (GHRHR), a class B GPCR | GHRH receptor (GHRHR), a class B GPCR |
| Molecular weight | ≈5,136 Da | ~5,039.6 Da |
| Half-life | ||
| Based on | Growth-hormone-releasing hormone | Native hormone |
Half-life bars are on a logarithmic scale across the molecules shown. Reference values for the native or representative form — educational only, not medical or dosing advice.
Common questions
- What is the difference between Tesamorelin and Growth-hormone-releasing hormone?
- Tesamorelin is an engineered analog based on Growth-hormone-releasing hormone; Growth-hormone-releasing hormone is an endogenous hormone. Tesamorelin signals at GHRH receptor (GHRHR), a class B GPCR; Growth-hormone-releasing hormone signals at GHRH receptor (GHRHR), a class B GPCR.
- How do the half-lives of Tesamorelin and GHRH compare?
- The reported circulating half-life of Tesamorelin is ~26-38 min (subcutaneous); Growth-hormone-releasing hormone is ~7–50 min. These are reference values for the native or representative form — educational only, not dosing advice.
- Is Tesamorelin the same as Egrifta?
- Egrifta is a brand name of Tesamorelin. This comparison describes the molecules, not branded products.
Prefer the other order? Growth-hormone-releasing hormone vs Tesamorelin. Or open the interactive comparison tool to add more molecules.